FINWIRES · TerminalLIVE
FINWIRES

Biome Australia Adds Greece Site to Lactiplantibacillus Plantarum Clinical Trial, Shares Jump 4%

By

Biome Australia (ASX:BIO) said the multi-center clinical trial of its first wholly proprietary strain, BMB18, or Lactiplantibacillus plantarum, was expanded from a single-centre study at La Trobe University in Melbourne with the activation of Harokopio University of Athens in Greece as a concurrent second site, according to a Wednesday Australian bourse filing.

The three-arm, double-blind, placebo-controlled study will test two BMB18 dosage levels against placebo across 240 participants over a six-week intervention period with a two-week follow-up.

Pre-clinical work showed that the strain has the potential for a triple mechanism of action across intestinal barrier function, immunomodulation, and antioxidant activity.

Recruitment is expected to begin this week at both sites, and the trial is expected to start in the fourth quarter of fiscal year 2026.

Its shares rose 4% in recent trading on Wednesday.

Related Articles

Asia

CTBC Financial Unit to Issue NT$9.6 Billion Bonds in June

CTBC Financial (TPE:2891) unit CTBC Bank will issue NT$9.6 billion in perpetual non-cumulative subordinated financial debentures on June 4, according to a Monday Taiwan Exchange filing.Shares gained about 2% in Tuesday's late morning trade.The 50th series subordinated bonds will carry a fixed annual coupon rate of 4.5% and have no maturity date.The bonds will be issued at face value, with each debenture carrying a denomination of NT$10 million.Proceeds will be used to strengthen its capital structure and replenish working capital.CTBC Bank said the notes may be redeemed after seven years, subject to regulatory approval.

TPE:2891
Asia

COSCO Shippig Specialized Carriers Plans Bond Issue of Up to 5 Billion Yuan

COSCO Shipping Specialized Carriers (SHA:600428) plans to register for issuance up to 5 billion yuan in bonds with a maximum term of 20 years.Proceeds will be used for repaying debts, replenishing working capital, paying ship construction costs and other permitted purposes, according to a Tuesday filing with the Shanghai bourse.The registration is valid for two years.

SHA:600428
Asia

Infratil's Fiscal 2026 Total Proportionate EBITDAF Meets Expectations, Jefferies Says

Infratil's (ASX:IFT, NZE:IFT) fiscal 2026 total proportionate earnings before interest, tax, depreciation, amortization, and fair value adjustments (EBITDAF) of NZ$919.3 million was in line with consensus of NZ$918.3 million, Jefferies said in a note on Tuesday.The company's EBITDAF increased 170% in the fiscal year with contributions from new projects completed in March and April 2025. Development EBITDAF losses of NZ$70 million was better than expected.Infratil swung to a profit of NZ$0.558 per share in fiscal 2026 from a loss of NZ$0.315 a year earlier. Revenue for the 12 months ended March 31 was NZ$3.04 billion, compared with NZ$2.86 billion a year earlier.The investment firm retained its buy rating on Infratil and its price targets of AU$14.40 and NZ$17.30.Infratil's Australian and New Zealand shares were each down 6% in recent Tuesday trade.

ASX:IFTNZE:IFT